STUDY OF REHABILITATION OF ONCOGYNECOLOGICAL DISEASES AMONG THE POPULATION AND EVIDENCE-BASED MEDICINE IN DIAGNOSTICS
- Authors
-
-
Djalilova Gulchekhra Azamovna
2nd Issue Department of Public Health and Healthcare Management Tashkent State Medical University
Author
-
- Keywords:
- Oncogynecological diseases; evidence-based medicine; early diagnosis; rehabilitation; clinical guidelines; quality of life
- Abstract
-
Oncogynecological diseases represent a significant public health challenge due to their high morbidity, complex clinical course, and substantial impact on quality of life. This study aims to analyze the role of evidence-based medicine in the diagnosis and rehabilitation of oncogynecological diseases among the population. The assessment is based on contemporary clinical guidelines, systematic reviews, and high-quality clinical studies evaluating diagnostic accuracy, treatment outcomes, and rehabilitation effectiveness in gynecologic oncology. Particular attention is given to evidence-based diagnostic algorithms, imaging and biomarker utilization, and multidisciplinary rehabilitation approaches addressing physical, psychological, and social aspects of recovery. The findings indicate that the integration of evidence-based diagnostic strategies enables earlier detection and more accurate disease staging, while rehabilitation programs supported by robust clinical evidence significantly improve functional outcomes, treatment tolerance, and quality of life. The results underscore that comprehensive implementation of evidence-based medicine across diagnostic and rehabilitative stages is essential for optimizing outcomes and reducing the long-term burden of oncogynecological diseases.
- References
-
1.
American Cancer Society. (2022). Cancer treatment and survivorship facts & figures 2022–2024. American Cancer Society.
2.
European Society of Gynaecological Oncology. (2023). ESGO guidelines for the management of gynecological cancers. International Journal of Gynecological Cancer, 33(3), 345–378. https://doi.org/10.1136/ijgc-2022-004190
3.
Ferlay, J., Colombet, M., Soerjomataram, I., et al. (2021). Global cancer statistics 2020. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
4.
Guyatt, G., Oxman, A. D., Kunz, R., et al. (2008). What is “quality of evidence” and why is it important? BMJ, 336(7651), 995–998. https://doi.org/10.1136/bmj.39490.551019.BE
5.
Koh, W. J., Abu-Rustum, N. R., Bean, S., et al. (2019). NCCN guidelines insights: Cervical cancer. Journal of the National Comprehensive Cancer Network, 17(1), 64–84. https://doi.org/10.6004/jnccn.2019.0003
6.
McGee, S. F., Tang, A., & Morris, E. (2020). Evidence-based rehabilitation in gynecologic oncology survivors. Gynecologic Oncology, 158(2), 395–402. https://doi.org/10.1016/j.ygyno.2020.05.019
7.
Ташпулатова, Ф. К., Садыков, А. С., & Галиуллин, Т. И. (2017). МЕДИКО-СОЦИАЛЬНЫЕ АСПЕКТЫ ТУБЕРКУЛЕЗА ЛЕГКИХ И ВИЧ. Фтизиатрия и пульмонология, (2), 136-136.
8.
Bekembayeva, G. S., & Tashpulatova, F. K. (2021). PROGNOSIS OF RESISTANT TUBERCULOSIS COURSE AMONG CHILDREN AND TEENAGERS. Новый день в медицине, (1), 48-51.
9.
Khomova, N., Tashpulatova, F., & Sultanov, S. (2017). Compliance-is patient adherence to treatment, as well as partnerships between doctor and patient.
10.
Ташпулатова, Ф. К., Галиулин, Т. И., & Жумаев, О. А. (2018). АССОЦИАЦИЯ РИСКА РАЗВИТИЯ КАЗЕОЗНОЙ ПНЕВМОНИИ ПРИ ТУБЕРКУЛЕЗЕ ЛЕГКИХ С ГЕНЕТИЧЕСКИМИ МАРКЕРАМИ. Интернаука, (14-1), 52-53.
11.
Вахабов, А. А., & Ташпулатова, Ф. К. (2018). Поражение печени у больных туберкулезом легких при побочных реакциях от противотуберкулезных препаратов. Молодой ученый, (3), 91-93.
12.
Хомова, Н. А., Коломиец, В. М., & Ташпулатова, Ф. К. (2020). Приверженность к лечению больных туберкулезом как фактор риска снижения его эффективности. In Университетская наука: взгляд в будущее (pp. 314-319).
13.
Tashpulatova, F., Shamshieva, N., Mukhteremova, V., Medvedeva, N., & Kurbanov, A. (2021). Phytotherapy in the Complex Treatment of Patients with Drug-Resistant Forms of Pulmonary Tuberculosis. Annals of the Romanian Society for Cell Biology, 25(1), 367-372.
14.
Ташпулатова, Ф. К., Жалолов, А. Ж., Медведева, Н. В., & Долгушева, Ю. В. (2016). Уровень комплаенса у больных с лекарственно устойчивым туберкулезом. In Медицина: вызовы сегодняшнего дня (pp. 46-50).
15.
Tashpulatova, F. K. (2003). Prevention of adverse reactions of antituberculous drugs in pulmonary tuberculosis in patients with different genetic background. Problemy tuberkuleza i boleznei legkikh, (6), 17-20.
16.
Ташпулатова, Ф. К. (2017). Выявление туберкулеза легких в общесоматических лечебных учреждениях. Молодой ученый, (3), 236-238.
17.
Ташпулатова, Ф. К., & Абдусаломова, М. И. (2020). Частота и характер побочных реакций от противотуберкулезных лекарственных средств у больных детей туберкулезом. Новый день в медицине, 2(30), 544-547.
18.
Ташпулатова, Ф. К., & Абдусаломова, М. И. (2020). Частота и характер побочных реакций от противотуберкулезных лекарственных средств у больных детей туберкулезом. Новый день в медицине, 2(30), 544-547.
- Downloads
- Published
- 2026-02-11
- Issue
- Vol. 2 No. 2 (2026)
- Section
- Articles
- License
-
This work is licensed under a Creative Commons Attribution 4.0 International License.
